Skip to main content

Swiss Proteomics Firm Biognosys Raises $3M in Series A

NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys has raised CHF2.7 million ($3 million) in a Series A round, it announced on Monday.

Participants in the round include Hellmut Kirchner, the co-founder of venture fund Techno Venture Management; Redalpine Capital I, which led Biognosys' seed funding in 2009; ZKB, the venture arm of Cantonal Bank of Zurich; Syngenta Ventures; and private investors.

"With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth," Oliver Rinner, the company's CEO, said in a statement. He did not provide further details about the use of the funds.

In connection with the funding, Biognosys also announced additions to its board including Kirchner, Ignacio Martinez, a principal in Syngenta Ventures, and Harry Welten, CFO of Cytos Biotechnology.

Biognosys was spun out of the Swiss Federal Institute of Technology in 2008 and provides targeted mass spectrometry-based services to companies operating in the diagnostics, pharma, healthcare, biotechnology, and agricultural spaces. Customers include Novartis, Pfizer, Integrated Diagnostics, and Philips, according to its website.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.